• 1
    American Cancer Society. Cancer facts and figures—2001. Atlanta: American Cancer Society, 2001.
  • 2
    Phillips J, Smith ED. Breast cancer control and African American women. Cancer Invest 2001; 19: 27380.
  • 3
    HaynesMA, SmedleyBD, editors. The unequal burden of cancer: an assessment of NIH research and programs for ethnic minorities and the medically underserved. Washington, DC: National Academic Press, 1999.
  • 4
    Moormeier J. Breast cancer in black women. Ann Intern Med 1996; 15: 897905.
  • 5
    Wojcik B, Spinks M, Otenberg S. Breast cancer survival analysis for African American and white women in an equal access health care system. Cancer 1998; 82: 13108.
  • 6
    Breen N, Wesley MN, Merrill RM, Johnson K. The relationship of socioeconomic status and access to minimum expected therapy among female breast cancer patients in the National Institute Black-White Survival Study. Ethnic Dis 1999; 9: 11125.
  • 7
    American Cancer Society. Cancer and the socioeconomically disadvantaged. Atlanta: American Cancer Society: Atlanta, GA, 1990.
  • 8
    Lamin DR, Mathews HF, Mitchell J, Swanson MS, Swanson FH, Edwards MS. Influence of socio-economic and cultural factors on racial differences in late stage presentation of breast cancer. JAMA 1998; 279: 18017.
  • 9
    Chen VW, Correa P, Kurman RJ, Wu XC, Eley J, Austin D, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemol Biomarkers Prevent 1994; 3: 12735.
  • 10
    Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic and black women in the United States. J Natl Cancer Inst 1994; 86: 70512.
  • 11
    Hunter GP, Redmond CK, Chen VW, Austin DF, Greenberg RS, Correa P, et al. Breast cancer factors associated with stage of diagnosis in black and white women. Black-White Survival Study Group. J Natl Cancer Inst 1993;85: 112937.
  • 12
    Thorpe SM. Estrogen and progesterone receptor determinations in breast cancer: technology, biology, and clinical significance. Acta Oncol 1988; 27: 119.
  • 13
    McGuire WL. Prognostic factors in breast cancer. Cancer Surveys 1986; 5: 52736.
  • 14
    Hawkins RA. Receptors in the management of breast cancer. Br J Hosp Med 1985; 34: 1604.
  • 15
    Savage N, Levin J, De Moor NG, Lange M. Cytosolic estrogen receptor content of breast cancer tissue in blacks and white. South Afr Med J 1981; 59: 6234.
  • 16
    Beverly LN, Flanders D, Go RCP, Soong SI. A comparison of estrogen and progesterone receptors in black and white breast cancer patients. Am J Pub Health 1987; 77: 3513.
  • 17
    Gapstur SM, Dupuis J, Gann P, Collila S, Winchester D. Hormone receptor status of breast tumors in black, Hispanic and Non-Hispanic white women. Cancer 1995; 77: 146571.
  • 18
    Dotzlaw H, Leygue E, Watson P, Murphy L. Expression of estrogen receptor beta in human breast tumors. J Clin Endocrinol Metab 1997; 82: 23714.
  • 19
    McGuire WL, Chamness GC, Fuqua SAW. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991; 5: 15717.
  • 20
    Fuqua SAW, Fitzgerald SD, Chammness GC, Tandon AK, McDonnell DP, Nawaz Z, et al. Variant human breast tumor estrogen receptor with constitutive activity. Cancer Res 1991; 51: 1059.
  • 21
    Castles CG, Fuqua SAW, Klot D, Hill SM. Expression of a constitutionally active estrogen receptor variant in the estrogen receptor negative BT-20 human breast cancer cell line. Cancer Res 1993; 53: 5939.
  • 22
    Leygue E, Huang A, Murphy LC, Watson PH. Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res 1996; 56: 43247.
  • 23
    Poola I, Koduri S, Chatra S, Clarke R. Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using spliced targeted primer approach. J Steroid Biochem Mol Biol 2000; 72: 24958.
  • 24
    Pfeffer U, Fecarotta E, Vidali G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and MCF-7 cells. Cancer Res 1995; 55: 215865.
  • 25
    Gotteland M, Desuty G, Delarue JC, Liu L, May E. Human estrogen receptor messenger RNA variants in both normal and tumor tissues. Mol Cell Endocrinol 1995; 112: 113.
  • 26
    Speirs V, Adams IP, Walton DS, Atkin SL. Identification of wild-type and exon 5 deletion variants of beta estrogen receptor in normal human mammary gland. J Clin Endocrinol Metab 2000; 85: 16015.
  • 27
    Lu B, Dotzlaw LE, Murphy LK, Murphy LC, Watson PH. Estrogen receptor beta mRNA variants in human and murine tissues. Mol Cell Endocrinol 1998; 7: 20511.
  • 28
    Vladusic EA, Hombsby AE, Guerra-Vladusic FK, Lupa R. Expression of estrogen receptor beta mRNAs in breast cancer. Cancer Res 1998; 58: 2104.
  • 29
    Fuqua SAW, Schiff R, Parra I, Friedrichs WE, Su JL, McKee DD, et al. Expression of wild type estrogen receptor beta and variant isoform proteins in human breast cancer. Cancer Res 1999; 59: 54258.
  • 30
    Kuiper GG, Carlson B, Grandien K, Enmark E, Haggblad A, Nilsson S, et al. Comparison of the ligand specificity and transcript tissue distribution of estrogen receptor beta. Endocrinology 1997; 138: 8639.
  • 31
    Paech, K., Webb., P., Kuiper, GG., and others differential ligand activation of estrogen receptors ER alpha and beta in AP-1 sites. Science 1997; 277: 150810.
  • 32
    Cowley SM, Parker MG. A comparison of transcriptional activities by ERα and ERβ. J Steroid Biochem Mol Biol 1999; 69: 16575.
  • 33
    Gustafsson JA, Warner M. Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer. J Steroid Biochem Mol Biol 2000; 30: 2458.
  • 34
    Bollig A, Miksicek RJ. An estrogen receptor-α splicing variant mediates both positive and negative effects on gene transcription. Mol Endocrinol 2000; 14: 63449.
  • 35
    Williams DM, Koduri S, Li Z, Hankins WD, Poola I. Primer design strategies for the amplification of alternatively spliced molecules. Anal Biochem 1999; 271: 1947.
  • 36
    Koduri S, Fuqua SAW, Poola I. Alterations in the estrogen receptor alpha mRNA in the breast tumors of African American women. J Cancer Res Clin Oncol 2000; 126: 2917.
  • 37
    Koduri S, Poola I. Quantitation of alternatively spliced estrogen receptor alpha mRNAs as separate gene populations. Steroids 2001; 66: 1723.
  • 38
    Poola I, Williams DM, Koduri S, Ramprakash J, Taylor RE, Hankins WD. Quantitation of estrogen receptor mRNA copy numbers in breast cancer cell lines and tumors. Anal Biochem 1998; 258: 20915.
  • 39
    Poola I, Speirs V. Expression of alternatively spliced ERα mRNAs is increased in breast cancer tissues. J Steroid Biochem Mol Biol 2001; 78: 45969.
  • 40
    Ercolani L, Florence B, Denaro M, Alexander M. Isolation and complete sequence of functional human glyceraldehyde-3 phosphate dehydrogenase cDNA. J Biol Chem 1988; 263: 153358.
  • 41
    Green S, Walter P, Kumar V, Krust A, Bornert J-M, Argos P, et al. Human estrogen receptor cDNA: sequence, expression, and homology to v-erb-A. Nature 1986; 320: 1349.
  • 42
    Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, et al. Human estrogen receptor beta gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82: 425865.
  • 43
    Speirs V, Parks AT, Kerin MJ, Walton DS, Carleton P, Fox J, et al. Co-expression of estrogen receptor α and β: poor prognostic factors in human breast cancer. Cancer Res 1999; 59: 5258.
  • 44
    Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered estrogen receptor alpha and beta mRNA expression during human breast tumerigenesis. Cancer Res 1998; 58: 3197201.